Seres Therapeutics (MCRB) PT Lowered to $16 at Oppenheimer
Oppenheimer analyst Mark Breidenbach lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $16.00 (from $17.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)